Answers are grounded in this paper and cite their sources.
// Liping Lin 1, 4, * , Juanjuan Zhao 2, * , Ning Kong 3, 4 , Yan He 1, 4 , Jiazhu Hu 1, 4 , Fuxi Huang 1, 4 , Jianjun Han 1, 4 and Xiaolong Cao 1, 4 1 Department of Oncology, Panyu Central Hospital, Guangzhou, 511400, China 2 School of Nursing, Sun Yat-sen University, Guangzhou, 510000, China 3 Department of Ophthalmology, Panyu Central Hospital, Guangzhou, 511400, China 4 Cancer Institute of Panyu, Guangzhou, 511400, China * These authors contributed equally to this work Correspondence to: Liping Lin, email: linliping2017@tom.com Keywords: ALK-TKIs, interstitial lung disease, QTc prolongation, non-small-cell lung cancer, meta-analysis Received: April 16, 2017 Accepted: May 03, 2017 Published: May 29, 2017 ABSTRACT Background: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients. Results: A total of 1,770 patients from 8 clinical trials were included. The incidences of high-grade ILD and QTc prolongation was 2.5% (95% CI 1.7-3.6%), and 2.8% (95% CI 1.8-4.3%), respectively. Meta-analysis demonstrated that the use of ALK-TKIs in NSCLC patients significantly increased the risk of developing high-grade ILD (Peto OR, 3.27, 95%CI: 1.18–9.08, p = 0.023) and QTc prolongation (Peto OR 7.51, 95% CI, 2.16–26.15; p = 0.002) in comparison with chemotherapy alone. Materials and Methods: A systematic literature search was performed to identify related citations up to January 31, 2017. Data were extracted, and summary incidence rates, Peto odds ratios (Peto ORs), and 95% confidence intervals (CIs) were calculated. Conclusions: The use of ALK-TKIs significantly increases the risk of developing high-grade ILD and QTc prolongation in lung cancer patients. Clinicians should pay attention to the risks of severe ILD and QTc prolongation with the administration of these drugs.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: